605 related articles for article (PubMed ID: 16279781)
1. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
[TBL] [Abstract][Full Text] [Related]
2. Rational approach to discover multipotent anti-Alzheimer drugs.
Rosini M; Andrisano V; Bartolini M; Bolognesi ML; Hrelia P; Minarini A; Tarozzi A; Melchiorre C
J Med Chem; 2005 Jan; 48(2):360-3. PubMed ID: 15658850
[TBL] [Abstract][Full Text] [Related]
3. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors.
Dorronsoro I; Alonso D; Castro A; del Monte M; García-Palomero E; Martínez A
Arch Pharm (Weinheim); 2005 Jan; 338(1):18-23. PubMed ID: 15674800
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
6. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Camps P; Formosa X; Galdeano C; Muñoz-Torrero D; Ramírez L; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Huertas O; Dafni T; Luque FJ
J Med Chem; 2009 Sep; 52(17):5365-79. PubMed ID: 19663388
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Shao D; Zou C; Luo C; Tang X; Li Y
Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
[TBL] [Abstract][Full Text] [Related]
8. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.
Piazzi L; Rampa A; Bisi A; Gobbi S; Belluti F; Cavalli A; Bartolini M; Andrisano V; Valenti P; Recanatini M
J Med Chem; 2003 Jun; 46(12):2279-82. PubMed ID: 12773032
[TBL] [Abstract][Full Text] [Related]
9. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.
Alonso D; Dorronsoro I; Rubio L; Muñoz P; García-Palomero E; Del Monte M; Bidon-Chanal A; Orozco M; Luque FJ; Castro A; Medina M; Martínez A
Bioorg Med Chem; 2005 Dec; 13(24):6588-97. PubMed ID: 16230018
[TBL] [Abstract][Full Text] [Related]
10. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties.
Fernández-Bachiller MI; Pérez C; Campillo NE; Páez JA; González-Muñoz GC; Usán P; García-Palomero E; López MG; Villarroya M; García AG; Martínez A; Rodríguez-Franco MI
ChemMedChem; 2009 May; 4(5):828-41. PubMed ID: 19308922
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
Belluti F; Rampa A; Piazzi L; Bisi A; Gobbi S; Bartolini M; Andrisano V; Cavalli A; Recanatini M; Valenti P
J Med Chem; 2005 Jun; 48(13):4444-56. PubMed ID: 15974596
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
[TBL] [Abstract][Full Text] [Related]
13. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Ramírez L; Viayna E; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Bidon-Chanal A; Huertas O; Dafni T; Luque FJ
Chem Biol Interact; 2010 Sep; 187(1-3):411-5. PubMed ID: 20167211
[TBL] [Abstract][Full Text] [Related]
14. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation.
Xie Q; Wang H; Xia Z; Lu M; Zhang W; Wang X; Fu W; Tang Y; Sheng W; Li W; Zhou W; Zhu X; Qiu Z; Chen H
J Med Chem; 2008 Apr; 51(7):2027-36. PubMed ID: 18333606
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.
Luo W; Li YP; He Y; Huang SL; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
Bioorg Med Chem; 2011 Jan; 19(2):763-70. PubMed ID: 21211982
[TBL] [Abstract][Full Text] [Related]
16. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.
Bolognesi ML; Cavalli A; Valgimigli L; Bartolini M; Rosini M; Andrisano V; Recanatini M; Melchiorre C
J Med Chem; 2007 Dec; 50(26):6446-9. PubMed ID: 18047264
[TBL] [Abstract][Full Text] [Related]
17. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation.
Bolognesi ML; Andrisano V; Bartolini M; Banzi R; Melchiorre C
J Med Chem; 2005 Jan; 48(1):24-7. PubMed ID: 15633997
[TBL] [Abstract][Full Text] [Related]
18. Potent beta-amyloid modulators.
García-Palomero E; Muñoz P; Usan P; Garcia P; Delgado E; De Austria C; Valenzuela R; Rubio L; Medina M; Martínez A
Neurodegener Dis; 2008; 5(3-4):153-6. PubMed ID: 18322376
[TBL] [Abstract][Full Text] [Related]
19. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.
Fernández-Bachiller MI; Pérez C; Monjas L; Rademann J; Rodríguez-Franco MI
J Med Chem; 2012 Feb; 55(3):1303-17. PubMed ID: 22243648
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
